Open-Label Safety Study of AXS-05 in Subjects With TRD

• Status: Enrolling by invitation
• Trial end date: 2022-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with treatment resistant depression (TRD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Axsome Therapeutics, Inc.
• Treatments: Bupropion; Dextromethorphan

Criteria

• Continued depression despite treatment with antidepressants in the current depressive episode

• Agree to use adequate method of contraception for the duration of the study

• Additional criteria may apply